Human Technopole

Meet Fabio Marcuccio, Postdoctoral Fellow at the Legnini Group (Genomics Research Centre, Functional Genomics Programme), who has been awarded a prestigious Marie Skłodowska-Curie Actions Postdoctoral Fellowship for the project “Regulation of mRNA homeostasis by poly(A) binding proteins”. The €193,643.28 grant will support a 24-month research programme aimed at uncovering how cells keep messenger RNA (mRNA) levels stable despite constant changes in their environment.

Turning scientific discoveries into real-world therapies was the focus of the second international conference “Future Trends in Translational Medicine – From Molecules to Therapies,” held at the Complesso Universitario di San Giovanni a Teduccio in Naples on 30 -31 October 2025.

As 2025 comes to a close, we look back at a year shaped by connection, discovery and growth. At Human Technopole, progress happens when perspectives meet, between disciplines, technologies and people. Our holiday card captures this idea visually: what looks like a festive forest is actually a colon under the microscope, a structure that changes depending on how you look at it, reminding us that science often begins with a shift in perspective.

An international study co-led by scientists from Human Technopole reveals that colorectal tumours use both genetic and epigenetic strategies to evade immune detection almost immediately after they transform into cancerous. The results, published in Nature Genetics, challenge previous notions that immune evasion occurs gradually over time.

Human Technopole researchers Nereo Kalebic and Blagoje Soskic have been awarded $1,319,010 by the Gilbert Family Foundation (GFF) through the Next-Generation NF1 Models Initiative. Their funded project “Assembloid Platform to Model Cellular Interactions Driving NF1 Glioma Pathology” focuses on developing the first 3D cell culture model of Neurofibromatosis type 1 (NF1), a genetic cancer predisposition syndrome that affects the central and peripheral nervous systems and increases the risk of high-grade gliomas.